Physician
Family Medicine
Dr. Karen L. MacKenzie, MD
|
|
Give Review
Karen L. MacKenzie, MD practices Family Medicine. He graduated from University of Minnesota Medical School. University of Minnesota Medical School is ranked 40/10 in Research/PrimaryCare. He received awards:"CMS Meaningful Use Stage 1 Certification". Karen MacKenzie is a published physician. He published 38 publications, including: 'V-myc in a simple, single gene retroviral vector causes rapid induction of leukemia and concomitant apoptosis following bone marrow transplantation.'
Publications
- Induction of Vascular Endothelial Growth Factor Secretion by Childhood Acute Lymphoblastic Leukemia Cells via the FLT-3 Signaling Pathway.
- p53 independent epigenetic repression of p21WAF1 in T-cell acute lymphoblastic leukemia.
- SIRT1 Promotes N-Myc Oncogenesis through a Positive Feedback Loop Involving the Effects of MKP3 and ERK on N-Myc Protein Stability.
- ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer.
- A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.
- p53 determines multidrug sensitivity of childhood neuroblastoma.
- Telomere-driven karyotypic complexity concurs with p16INK4a inactivation in TP53-competent immortal endothelial cells.
- Osteopetrotic mouse stroma with thrombopoietin, c-kit ligand, and flk-2 ligand supports long-term mobilized CD34+ hematopoiesis in vitro.
- Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid rec...
- Inactivation of p16INK4a, with retention of pRB and p53/p21cip1 function, in human MRC5 fibroblasts that overcome a telomere-independent crisis during immortalization.
- Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies.
- Limited proliferation and telomere dysfunction following telomerase inhibition in immortal murine fibroblasts.
- Ex vivo expansion of stem and progenitor cells in co-culture of mobilized peripheral blood CD34+ cells on human endothelium transfected with adenovectors expressing th...
- The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells.
- Targeting telomerase in hematologic malignancy.
- Mild hyperoxia limits hTR levels, telomerase activity, and telomere length maintenance in hTERT-transduced bone marrow endothelial cells.
- FLT-3: a new focus in the understanding of acute leukemia.
- Mutant N-ras preferentially drives human CD34+ hematopoietic progenitor cells into myeloid differentiation and proliferation both in vitro and in the NOD/SCID mouse.
- Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras.
- Methotrexate selection of long-term culture initiating cells following transduction of CD34(+) cells with a retrovirus containing a mutated human dihydrofolate reducta...
- Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase.
- Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice.
- Adenoviral vector-mediated gene transfer to primitive human hematopoietic progenitor cells: assessment of transduction and toxicity in long-term culture.
- Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation.
- Telomere length of cord blood-derived CD34(+) progenitors predicts erythroid proliferative potential.
- Optimizing conditions for gene transfer into human hematopoietic cells.
- Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
- An internal deletion enhances the transcriptional activity of a recombinant retrovirus in hematopoietic cells in vivo.
- Clonal variation in phenotype and life span of human embryonic fibroblasts (MRC-5) transduced with the catalytic component of telomerase (hTERT).
- Retroviral transduction of hematopoietic progenitor cells with mutant p53 promotes survival and proliferation, modifies differentiation potential and inhibits apoptosis.
- Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo.
- Both myeloproliferative disease and leukemia are induced by transplantation of bone marrow cells expressing v-myc.
- V-myc in a simple, single gene retroviral vector causes rapid induction of leukemia and concomitant apoptosis following bone marrow transplantation.
- Myeloproliferative disease and myelodysplastic syndrome induced by transplantation of bone marrow cells expressing mutant p53.
- Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect.
- The p53 status of cultured human premalignant oral keratinocytes.
- Towards the large-scale synthesis of carbon nanotubes in fluidised beds.
Schools
University of Mn Med Sch
Hennepin Co Med Center
Doctors Specialties
- Family Medicine
Accepted Insurances
- Choice Plus POS II
- Assurant Health
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Cross Accord
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- First Health (Coventry Health Care) PPO
- HealthPartners
- Humana
- Mail Handlers Benefit Plan (MHBP)
- Medica
- Medicare MCR
- Principal Life
- Tricare
- Choice Plus POS
- Navigate POS
- Options PPO
- United Healthcare
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Hennepin County Medical Center -
University of Minnesota Medical School
Hospital
-
Regions Hospital
Drug Facts
| NPI NUMBER | 1396711628 | |
| NPPES Provider LastName | MACKENZIE | |
| NPPES Provider FirstName | KAREN | |
| NPPES Provider ZIPCode | 551132460 | |
| NPPES Provider State | MN | |
| Specialty Description | Family Practice | |
| Total Claim Count | 6759.0 | |
| Distinct Opioid Count | 5.0 | |
| Opioid Claim Count | 137.0 | |
| Percent Opioid Claims | 2.03 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1396711628 |
| Last Name Of The Provider | MACKENZIE |
| First Name Of The Provider | KAREN |
| View All |
Similar Doctors
|
|
Dr. Christopher G. Foss, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anita S. MacDonald, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jose T. Bernard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katelyn E. Bezek, MD |
|
|
Dr. Maria V. Vu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Linnea K. Engel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marianito S. Chua, MD |
|
|
Dr. Martin M. Urberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ellen R. Stubbs, MD |
|
|
Dr. Shehbana Mahmood, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicole Chaisson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shumona R. Saha, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laurie D. Kaiser Sund, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julia K. Perpich, MD
This Doctor is OpenDoctor Recommended.
|